SENS-AI
LHC Trading Update Neutral

LIFE HEALTHCARE GROUP HOLDINGS LIMITED - Trading update and statement for the 6 months ended March 2026 and changes to the board of Life Healthcare Funding

Life Healthcare Group Holdings Limited
Full analysis

What this filing means

Life Healthcare expects normalised earnings to increase by 6% to 10% through improved margins, despite a R130 million revenue hit from a funder placed under curatorship.

Life Healthcare is making more profit from its core hospital operations by running them more efficiently and taking in higher-revenue surgical cases. However, they lost some overall revenue because one of the medical schemes paying for patients ran into financial trouble.

Bull case

  • Normalised earnings per share (NEPS) are expected to increase by 6% to 10%, reflecting underlying profitability despite top-line headwinds.
  • Normalised EBITDA increased by 4.9% to 5.3%, driven by successful operational efficiencies and margin improvement projects.
  • The southern Africa normalised EBITDA margin improved by approximately 0.5% compared to the prior period.
  • Activity trends showed a positive recovery in the second quarter, with weighted average occupancy exceeding 70%.
  • Average tariffs increased by 3.3%, which combined with a shift toward surgical cases, drove a 4.0% increase in revenue per paid patient day.

Bear case

  • The group suffered a direct revenue reduction of approximately R130 million due to a funder being placed under curatorship.
  • Paid patient days (PPDs) declined by 0.4% on a like-for-like basis, driven by a 0.9% drop in acute hospital operations.
  • The group recorded R38 million in impairments specifically related to its non-acute businesses.
  • Statutory earnings metrics remain heavily distorted by prior-period fair value adjustments, requiring reliance on unaudited pro forma figures that management warns may not fairly present the financial position.
View original SENS announcement

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

Life Healthcare released a trading update projecting a 6% to 10% increase in normalised earnings per share and announced the completion of a scheduled board change at Life Healthcare Funding. The update reflects mixed operational conditions, where successful efficiency projects and a 0.5% EBITDA margin improvement have offset a 0.4% decline in paid patient days and a R130 million revenue reduction linked to a funder placed under curatorship. This is not a final audited results release, and the statutory headline metrics remain heavily distorted by prior-year pro forma adjustments relating to the Piramal liability. Investor Takeaway: Underlying margin resilience confirms operational efficiency is intact, though the curatorship funder drag highlights the company's vulnerability to external counterparty distress.

Informational filing with mixed underlying drivers. No immediate portfolio action is required as the positive margin expansion counterbalances the revenue headwinds.

Decision framework

Current stance: Filing Neutral

Key drivers

  • Normalised earnings per share (NEPS) are expected to increase by 6% to 10%, reflecting underlying profitability despite top-line headwinds.
  • Normalised EBITDA increased by 4.9% to 5.3%, driven by successful operational efficiencies and margin improvement projects.
  • The southern Africa normalised EBITDA margin improved by approximately 0.5% compared to the prior period.

Key risks

  • The group suffered a direct revenue reduction of approximately R130 million due to a funder being placed under curatorship.
  • Paid patient days (PPDs) declined by 0.4% on a like-for-like basis, driven by a 0.9% drop in acute hospital operations.
  • The group recorded R38 million in impairments specifically related to its non-acute businesses.

What would change the view

  • Guidance and cash-flow quality both improve materially from current baseline.
  • Subsequent filings remove current uncertainty and confirm durable execution.
  • Market structure/positioning shifts enough to support a directional thesis.

Evidence from the filing

  • Normalised earnings per share (NEPS) are expected to increase by 6% to 10%, reflecting underlying profitability despite top-line headwinds.

    “The Group has improved its normalised EBITDA margin, and normalised earnings per share (NEPS) is expected to increase by between 6% and 10%.”

  • Normalised EBITDA increased by 4.9% to 5.3%, driven by successful operational efficiencies and margin improvement projects.

    “Normalised EBITDA(2) increased by between 4.9% and 5.3%, through a combination of operational efficiency and the impact of margin improvement projects”

  • The southern Africa normalised EBITDA margin improved by approximately 0.5% compared to the prior period.

    “contributing to an improvement in the southern Africa normalised EBITDA margin of c. 0.5% compared to the prior period.”

  • Activity trends showed a positive recovery in the second quarter, with weighted average occupancy exceeding 70%.

    “Activity trends improved in the second quarter, supported by a recovery in theatre minutes. Weighted average occupancy for H1-FY2026 was 67.5% (H1-FY2025: 68.8%(1)), with the second quarter exceeding 70%.”

  • Average tariffs increased by 3.3%, which combined with a shift toward surgical cases, drove a 4.0% increase in revenue per paid patient day.

    “The Group achieved an average tariff increase of 3.3%. Revenue per PPD increased by c. 4.0%(1) for the current period benefitting from the increase in surgical PPDs.”

  • The group suffered a direct revenue reduction of approximately R130 million due to a funder being placed under curatorship.

    “Revenue for H1-FY2026 increased by between 2.2% and 2.6% compared to the prior period, impacted by a reduction of c. R130 million of revenue from the funder placed under curatorship.”

  • Paid patient days (PPDs) declined by 0.4% on a like-for-like basis, driven by a 0.9% drop in acute hospital operations.

    “Paid patient days (PPDs) declined by c. 0.4%(1), primarily driven by the acute hospital operations, where PPDs declined by c. 0.9%(1)”

  • The group recorded R38 million in impairments specifically related to its non-acute businesses.

    “Impairments of non-acute businesses to the value of R38 million”

  • Statutory earnings metrics remain heavily distorted by prior-period fair value adjustments, requiring reliance on unaudited pro forma figures that management warns may not fairly present the financial position.

    “The pro forma information has been prepared for illustrative purposes only and, due to its nature, may not fairly present the Group's financial position, changes in equity, results of operations or cash flows.”
Category
Trading Update
Event posture
No Edge
Published
May 7, 2026

More on Life Healthcare Group Holdings Limited

Life Healthcare Group Holdings Limited (LHC) share price All Life Healthcare Group Holdings Limited SENS announcements

Related filings